# A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation

Source: https://onco.cc/trials/nct07231068/  
OnCo record `nct07231068` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Dositinib mesylate tablets in non-small-cell lung cancer, run by Henan Genuine Biotech Co., Ltd., now recruiting.

## Summary

A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation is a phase 1/2 interventional study registered as NCT07231068 by Henan Genuine Biotech Co., Ltd., with 153 participants planned, started 2022-10-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: Dositinib mesylate tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07231068
- Phase: 1/2
- Setting: A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study on the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutations
- Sponsor: Henan Genuine Biotech Co., Ltd.
- Enrolled: 153

## Sources

- ClinicalTrials.gov NCT07231068: https://clinicaltrials.gov/study/NCT07231068

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Henan Genuine Biotech](https://onco.cc/companies/henan-genuine-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07231068.json